- Home
- RRC vs PHIO Comparison
RRC vs PHIO Comparison
Compare RRC & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRC | PHIO |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 12.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RRC | PHIO |
|---|---|---|
| Price | $37.56 | $1.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 3 |
| Target Price | ★ $41.29 | $10.67 |
| AVG Volume (30 Days) | 3.2M | ★ 9.3M |
| Earning Date | 02-24-2026 | 03-30-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 19.84 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,891,506,000.00 | N/A |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $10.72 | N/A |
| P/E Ratio | $15.39 | ★ N/A |
| Revenue Growth | ★ 24.57 | N/A |
| 52 Week Low | $30.32 | $0.81 |
| 52 Week High | $43.50 | $4.19 |
Technical Indicators
Market Signals| Indicator | RRC | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 67.44 |
| Support Level | $35.71 | $0.81 |
| Resistance Level | $37.10 | $1.48 |
| Average True Range (ATR) | 1.13 | 0.10 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 51.58 | 83.14 |
Price Performance
Historical ComparisonAbout RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.2 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.